Anti-sclerotic Effect of Transforming Growth Factor-β Antibody in a Mouse Model of Bleomycin-Induced Scleroderma
- 1 July 1999
- journal article
- research article
- Published by Elsevier in Clinical Immunology
- Vol. 92 (1) , 6-13
- https://doi.org/10.1006/clim.1999.4720
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Animal Model of Sclerotic Skin. I: Local Injections of Bleomycin Induce Sclerotic Skin Mimicking SclerodermaJournal of Investigative Dermatology, 1999
- Transforming growth factor‐β: activity and efficacy in animal models of wound healingWound Repair and Regeneration, 1995
- Transforming growth factor-beta: recent progress and new challenges.The Journal of cell biology, 1992
- Interleukin‐1, Interleukin‐2, Interleukin‐4, Interleukin‐6, Tumor Necrosis Factor α, and Interferon‐γ Levels in Sera from Patients With SclerodermaArthritis & Rheumatism, 1992
- Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis.Journal of Clinical Investigation, 1990
- Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation.The Journal of Experimental Medicine, 1989
- Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.The Journal of Experimental Medicine, 1989
- Systemic scleroderma: Clinical and pathophysiologic aspectsJournal of the American Academy of Dermatology, 1988
- Flagellate pigmentation from intrapleural bleomycin: A light microscopy and electron microscopy studyJournal of the American Academy of Dermatology, 1985
- Cellular infiltrates in scleroderma skinArthritis & Rheumatism, 1977